Capstone Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.47M | Buy |
10,000
+7,500
| +300% | +$3.5M | 0.01% | 446 |
|
|
2025
Q4 | $1.13M | Sell |
2,500
-3,400
| -58% | -$1.47M | ﹤0.01% | 824 |
|
|
2025
Q3 | $2.31M | Buy |
5,900
+600
| +11% | +$251K | ﹤0.01% | 722 |
|
|
2025
Q2 | $2.36M | Sell |
5,300
-700
| -12% | -$323K | 0.01% | 593 |
|
|
2025
Q1 | $2.91M | Sell |
6,000
-8,300
| -58% | -$3.87M | 0.01% | 592 |
|
|
2024
Q4 | $5.76M | Buy |
14,300
+3,700
| +35% | +$1.72M | 0.01% | 497 |
|
|
2024
Q3 | $4.93M | Buy |
10,600
+1,200
| +13% | +$576K | 0.02% | 459 |
|
|
2024
Q2 | $4.41M | Buy |
9,400
+2,700
| +40% | +$1.17M | 0.01% | 489 |
|
|
2024
Q1 | $2.8M | Sell |
6,700
-8,100
| -55% | -$3.42M | 0.01% | 640 |
|
|
2023
Q4 | $6.02M | Buy |
14,800
+3,300
| +29% | +$1.22M | 0.02% | 468 |
|
|
2023
Q3 | $4M | Buy |
11,500
+3,000
| +35% | +$1.05M | 0.02% | 494 |
|
|
2023
Q2 | $2.99M | Buy |
8,500
+900
| +12% | +$303K | 0.01% | 523 |
|
|
2023
Q1 | $2.39M | Sell |
7,600
-4,800
| -39% | -$1.44M | 0.01% | 542 |
|
|
2022
Q4 | $3.58M | Buy |
12,400
+700
| +6% | +$213K | 0.03% | 500 |
|
|
2022
Q3 | $3.39M | Sell |
11,700
-800
| -6% | -$230K | 0.02% | 531 |
|
|
2022
Q2 | $3.52M | Sell |
12,500
-1,700
| -12% | -$455K | 0.02% | 524 |
|
|
2022
Q1 | $3.71M | Sell |
14,200
-27,000
| -66% | -$6.41M | 0.01% | 803 |
|
|
2021
Q4 | $9.05M | Sell |
41,200
-6,000
| -13% | -$1.17M | 0.02% | 642 |
|
|
2021
Q3 | $8.56M | Buy |
47,200
+14,900
| +46% | +$2.91M | 0.02% | 668 |
|
|
2021
Q2 | $6.51M | Buy |
32,300
+8,800
| +37% | +$1.84M | 0.01% | 655 |
|
|
2021
Q1 | $5.05M | Buy |
23,500
+8,900
| +61% | +$1.95M | 0.01% | 651 |
|
|
2020
Q4 | $3.45M | Sell |
14,600
-9,700
| -40% | -$2.23M | 0.01% | 719 |
|
|
2020
Q3 | $6.61M | Buy |
24,300
+4,500
| +23% | +$1.24M | 0.03% | 434 |
|
|
2020
Q2 | $5.75M | Buy |
19,800
+5,700
| +40% | +$1.55M | 0.04% | 388 |
|
|
2020
Q1 | $3.35M | Sell |
14,100
-35,200
| -71% | -$8.07M | 0.05% | 380 |
|
|
2019
Q4 | $10.8M | Buy |
49,300
+18,600
| +61% | +$3.76M | 0.06% | 347 |
|
|
2019
Q3 | $5.2M | Buy |
30,700
+13,400
| +77% | +$2.37M | 0.04% | 425 |
|
|
2019
Q2 | $3.17M | Buy |
17,300
+5,300
| +44% | +$927K | 0.02% | 605 |
|
|
2019
Q1 | $2.21M | Buy |
12,000
+6,400
| +114% | +$1.18M | 0.02% | 570 |
|
|
2018
Q4 | $928K | Buy |
5,600
+2,100
| +60% | +$364K | 0.01% | 639 |
|
|
2018
Q3 | $675K | Buy |
+3,500
| New | +$623K | 0.01% | 715 |
|
|
2014
Q3 | – | Sell |
-46,500
| Closed | -$4.4M | – | 507 |
|
|
2014
Q2 | $4.4M | Buy |
46,500
+31,500
| +210% | +$2.21M | 0.06% | 198 |
|
|
2014
Q1 | $1.06M | Buy |
+15,000
| New | +$1.19M | 0.01% | 292 |
|
Other funds holding VRTX
VCM
VPM
Capstone Investment Advisors's VRTX Position: Q1 2026 in Review
Capstone Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, buying an estimated $306K and bringing the position to 3,895 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #684.
Capstone Investment Advisors first reported a position in VRTX in Q1 2016 and has held it in 25 quarters since. The position peaked at $18.4M in Q3 2021. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Capstone Investment Advisors held 3,895 shares of Vertex Pharmaceuticals worth $1.74M as of Q1 2026.
- Capstone Investment Advisors bought 656 Vertex Pharmaceuticals shares in Q1 2026, an estimated $306K.
- Vertex Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #684 holding.
- Capstone Investment Advisors first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
- Capstone Investment Advisors's Vertex Pharmaceuticals position peaked at $18.4M in Q3 2021.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.